Tag Archives: 5-ALA

Protected: Fluorescence imaging & endoscopy for tumor visualization and diagnostics

There is no excerpt because this is a protected post.Introduction to fluorescence imaging Fluorescence is a phenomenon where substance that has absorbed certain wavelength of light emits it back at another wavelength. These substances are called fluorophores or fluorescent dyes. The emitted light has a longer wavelength than the absorbed one since some energy of the photon is lost in the process. The difference in wavelengths between absorbed and emitted light, called Stokes shift, allows very low background for fluorescence detection by separating it from the excitation light. The process of fluorescence generation is Continue reading →

Light penetration depth in brain with different photosensitizers

  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers. Continue reading →

ML7710 for glioblastoma treatment

Background   Professor Stummer on glioblastoma surgeries and iPDT:   Treatment protocol 20 patients were treated. 5-ALA (Gliolan) was administered at a dosage of 20 mg/kg body weight 4 hours before anesthesia. Craniotomy was performed using FGR, with aim of maximal safe resection of the fluorescent tumor. Once there was no visible fluorescence or only tumor-infiltrated fluorescence in the eloquent areas left, PDT was performed. 1-4 cylindrical diffuser were strategically inserted depending on the size and architecture of the resection cavity and fixed to a Continue reading →Customer case Research by: University Hospital Münster provides cutting-edge medical treatments for patients all over the world. The department of neurosurgery provides a full spectrum of neurosurgical care with interdisciplinary vascular and neuro-oncological specialization. Modulight products: ML7710, ML7710i Laser use: Randomized controlled PDT trials for both newly diagnosed and recurrent glioblastoma, as well as compassionate care for terminal glioblastoma patients. Link to the study: Professor Walter Stummer, MD, PhD Research topics: Professor Stummer is a world leader in his research fields, which include vascular neurosurgery, microneurosurgery, Continue reading →